These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38910730)

  • 1. Insulin Access Enhancement in India: Expert Views on Integrating Interchangeable Biosimilar Insulin Glargine.
    Prasanna Kumar KM; Chowdhury S; Bantwal G; Unnikrishnan AG; Kalra S; Aggarwal S; Singh AK; Pandit K; Shukla R; Vishwanathan V; Khobragade K; Sarda PS
    Cureus; 2024 May; 16(5):e60983. PubMed ID: 38910730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn.
    Matli MC; Wilson AB; Rappsilber LM; Sheffield FP; Farlow ML; Johnson JL
    J Diabetes Sci Technol; 2023 Mar; 17(2):490-494. PubMed ID: 34971335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective.
    Joshi SR; Mittra S; Raj P; Suvarna VR; Athalye SN
    Expert Opin Biol Ther; 2023; 23(8):693-704. PubMed ID: 35993301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability.
    White J; Goldman J
    J Pharm Technol; 2019 Feb; 35(1):25-35. PubMed ID: 34861004
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K; Bhimji H; Eurich D; Mansell H
    BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.
    Godman B; Haque M; Leong T; Allocati E; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Vassalo C; Bakar MA; Rahim SA; Sultana N; Deeba F; Khan MAH; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Rwegerera GM; do Nascimento RCRM; Dias Godói IP; Irfan M; Amu AA; Matowa P; Acolatse J; Incoom R; Sefah IA; Acharya J; Opanga S; Njeri LW; Kimonge D; Kwon HY; Bae S; Khuan KKP; Abubakar AR; Sani IH; Khan TA; Hussain S; Saleem Z; Malande OO; Piloya-Were T; Gambogi R; Hernandez Ortiz C; Alutuli L; Kalungia AC; Hoxha I; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Laius O; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuoliene K; Gulbinovič J; Wladysiuk M; Rutkowski J; Mardare I; Fürst J; McTaggart S; MacBride-Stewart S; Pontes C; Zara C; Tagoe ET; Banzi R; Wale J; Jakovljevic M
    Front Public Health; 2021; 9():671961. PubMed ID: 34249838
    [No Abstract]   [Full Text] [Related]  

  • 7. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
    Godman B; Wladysiuk M; McTaggart S; Kurdi A; Allocati E; Jakovljevic M; Kalemeera F; Hoxha I; Nachtnebel A; Sauermann R; Hinteregger M; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Slabý J; Nejezchlebova R; Krulichová IS; Laius O; Selke G; Langner I; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuolienė K; Gulbinovič J; Bonanno PV; Rutkowski J; Ingeberg S; Melien Ø; Mardare I; Fürst J; MacBride-Stewart S; Holmes C; Pontes C; Zara C; Pedrola MT; Hoffmann M; Kourafalos V; Pisana A; Banzi R; Campbell S; Wettermark B
    Biomed Res Int; 2021; 2021():9996193. PubMed ID: 34676266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus.
    D'Amico F; Solitano V; Magro F; Olivera PA; Halfvarson J; Rubin D; Dignass A; Al Awadhi S; Kobayashi T; Queiroz NSF; Calvo M; Kotze PG; Ghosh S; Peyrin-Biroulet L; Danese S
    J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37834994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on Biosimilar Insulins: A US Perspective.
    Zhang RM; Puri R; McGill JB
    BioDrugs; 2020 Aug; 34(4):505-512. PubMed ID: 32681425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective.
    Ponomareva E; Schmerold L; Sss S; Preblick R; Park S; Wilson L; Revel A
    J Med Econ; 2023; 26(1):1469-1478. PubMed ID: 37916295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials.
    Heinemann L; Davies M; Home P; Forst T; Vilsbøll T; Schnell O
    J Diabetes Sci Technol; 2023 Nov; 17(6):1649-1661. PubMed ID: 35818669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar vs originator insulins: Systematic review and meta-analysis.
    Yamada T; Kamata R; Ishinohachi K; Shojima N; Ananiadou S; Nom H; Yamauchi T; Kadowaki T
    Diabetes Obes Metab; 2018 Jul; 20(7):1787-1792. PubMed ID: 29536603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction of biosimilar insulins in Europe.
    Davies M; Dahl D; Heise T; Kiljanski J; Mathieu C
    Diabet Med; 2017 Oct; 34(10):1340-1353. PubMed ID: 28608570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars and access to biologic therapy in immune-mediated diseases.
    Vázquez-Sánchez R; Navarro-Dávila M; Herráiz ER; Merino-Bohórquez V; Borrás-Blasco J; Onteniente-González A; Iglesias-Lambarri A; Negro-Vega E
    Expert Opin Biol Ther; 2024 May; ():1-7. PubMed ID: 38698351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.
    Hernandez I; Gellad WF
    J Manag Care Spec Pharm; 2020 Feb; 26(2):154-159. PubMed ID: 32011961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
    Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
    BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.
    Dolinar R; Lavernia F; Edelman S
    Endocr Pract; 2018 Feb; 24(2):195-204. PubMed ID: 29466056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars and Novel Insulins.
    Ampudia-Blasco FJ
    Am J Ther; 2020; 27(1):e52-e61. PubMed ID: 31764128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.